Senior onderzoeker Huisartsenzorg
Publicatie
Publicatie datum
Comorbidities in multiple sclerosis patients within general practices in The Netherlands.
Lemmens, C.M.C., Mostert, J., Vanhommerig, J.W., Knottnerus, B., Jong, B. de. Comorbidities in multiple sclerosis patients within general practices in The Netherlands. Multiple Sclerosis Journal: 2024, 30(3 suppl.), p. 1174-1175. Abstract meeting of the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 18-20 September 2024, Copenhagen, Denmark
ABSTRACT:
Introduction
Patients with multiple sclerosis (MS) may face an increased risk of comorbidities due to the debilitating and chronic nature of the disease. An enhanced knowledge of prevalent comorbidities and infections in MS could offer new insights and improve MS management.
Objectives/Aims
To investigate the occurrence of comorbidities and infections in patients with multiple sclerosis (MS) in a
general practice setting, compared to matched control patients.
Methods
This retrospective database analysis was conducted using the 2019 Dutch Nivel-Primary Care Database, assessing comorbidities in MS patients versus non-MS matched controls, with regard to age- and sex-standardized prevalence rates and odds ratios between the two populations. Differences in incidence rates in infections were analyzed between MS and nonMS counterparts.
Results
A total of 3,013 individuals with MS were matched with 15,103 control patients in a primary care database. A heightened prevalence of comorbid chronic diseases in patients with MS was found, in particular in ophthalmological (OR 1.57; 95% CI 1.38 – 1.79), neurological (OR 1.44; 95% CI 1.25 – 1.66), oncological (OR 1.21 (1.07 – 1.37); in particular kidney cancer, non-leukemia hematological malignancy and skin cancer) and psychiatric diseases (OR 1.17; 95% CI 1.03 – 1.33). Both older age and female sex were associated with higher risk of comorbidities in MS patients. In our cohort, the prevalence of autoimmune disorders was not statistically higher in MS patients compared to matched controls. The crude annual rate of infections in patients with MS was higher than in matched controls (respectively 0.6 versus 0.3 annual infectious episodes), with a heightened risk of infections of 86% in MS patients.
Conclusion
Patients living with MS have more chronic comorbidities and are at a considerable heightened risk of infections. The increased risk of certain oncological diseases in our cohort warrants further research, with a focus on demographic risk factors and the influence of disease-modifying treatments.
Prevention and treatment of these diseases may potentially ameliorate disease course and prognosis of MS.
Disclosure of interest
BdJ receives research funding from the Dutch MS Research Foundation, National MS Foundation, Dutch Multiple Sclerosis Association, Zorgverzekeraars Nederland (i.e. umbrella organization of health insurers in the Netherlands).
Introduction
Patients with multiple sclerosis (MS) may face an increased risk of comorbidities due to the debilitating and chronic nature of the disease. An enhanced knowledge of prevalent comorbidities and infections in MS could offer new insights and improve MS management.
Objectives/Aims
To investigate the occurrence of comorbidities and infections in patients with multiple sclerosis (MS) in a
general practice setting, compared to matched control patients.
Methods
This retrospective database analysis was conducted using the 2019 Dutch Nivel-Primary Care Database, assessing comorbidities in MS patients versus non-MS matched controls, with regard to age- and sex-standardized prevalence rates and odds ratios between the two populations. Differences in incidence rates in infections were analyzed between MS and nonMS counterparts.
Results
A total of 3,013 individuals with MS were matched with 15,103 control patients in a primary care database. A heightened prevalence of comorbid chronic diseases in patients with MS was found, in particular in ophthalmological (OR 1.57; 95% CI 1.38 – 1.79), neurological (OR 1.44; 95% CI 1.25 – 1.66), oncological (OR 1.21 (1.07 – 1.37); in particular kidney cancer, non-leukemia hematological malignancy and skin cancer) and psychiatric diseases (OR 1.17; 95% CI 1.03 – 1.33). Both older age and female sex were associated with higher risk of comorbidities in MS patients. In our cohort, the prevalence of autoimmune disorders was not statistically higher in MS patients compared to matched controls. The crude annual rate of infections in patients with MS was higher than in matched controls (respectively 0.6 versus 0.3 annual infectious episodes), with a heightened risk of infections of 86% in MS patients.
Conclusion
Patients living with MS have more chronic comorbidities and are at a considerable heightened risk of infections. The increased risk of certain oncological diseases in our cohort warrants further research, with a focus on demographic risk factors and the influence of disease-modifying treatments.
Prevention and treatment of these diseases may potentially ameliorate disease course and prognosis of MS.
Disclosure of interest
BdJ receives research funding from the Dutch MS Research Foundation, National MS Foundation, Dutch Multiple Sclerosis Association, Zorgverzekeraars Nederland (i.e. umbrella organization of health insurers in the Netherlands).
ABSTRACT:
Introduction
Patients with multiple sclerosis (MS) may face an increased risk of comorbidities due to the debilitating and chronic nature of the disease. An enhanced knowledge of prevalent comorbidities and infections in MS could offer new insights and improve MS management.
Objectives/Aims
To investigate the occurrence of comorbidities and infections in patients with multiple sclerosis (MS) in a
general practice setting, compared to matched control patients.
Methods
This retrospective database analysis was conducted using the 2019 Dutch Nivel-Primary Care Database, assessing comorbidities in MS patients versus non-MS matched controls, with regard to age- and sex-standardized prevalence rates and odds ratios between the two populations. Differences in incidence rates in infections were analyzed between MS and nonMS counterparts.
Results
A total of 3,013 individuals with MS were matched with 15,103 control patients in a primary care database. A heightened prevalence of comorbid chronic diseases in patients with MS was found, in particular in ophthalmological (OR 1.57; 95% CI 1.38 – 1.79), neurological (OR 1.44; 95% CI 1.25 – 1.66), oncological (OR 1.21 (1.07 – 1.37); in particular kidney cancer, non-leukemia hematological malignancy and skin cancer) and psychiatric diseases (OR 1.17; 95% CI 1.03 – 1.33). Both older age and female sex were associated with higher risk of comorbidities in MS patients. In our cohort, the prevalence of autoimmune disorders was not statistically higher in MS patients compared to matched controls. The crude annual rate of infections in patients with MS was higher than in matched controls (respectively 0.6 versus 0.3 annual infectious episodes), with a heightened risk of infections of 86% in MS patients.
Conclusion
Patients living with MS have more chronic comorbidities and are at a considerable heightened risk of infections. The increased risk of certain oncological diseases in our cohort warrants further research, with a focus on demographic risk factors and the influence of disease-modifying treatments.
Prevention and treatment of these diseases may potentially ameliorate disease course and prognosis of MS.
Disclosure of interest
BdJ receives research funding from the Dutch MS Research Foundation, National MS Foundation, Dutch Multiple Sclerosis Association, Zorgverzekeraars Nederland (i.e. umbrella organization of health insurers in the Netherlands).
Introduction
Patients with multiple sclerosis (MS) may face an increased risk of comorbidities due to the debilitating and chronic nature of the disease. An enhanced knowledge of prevalent comorbidities and infections in MS could offer new insights and improve MS management.
Objectives/Aims
To investigate the occurrence of comorbidities and infections in patients with multiple sclerosis (MS) in a
general practice setting, compared to matched control patients.
Methods
This retrospective database analysis was conducted using the 2019 Dutch Nivel-Primary Care Database, assessing comorbidities in MS patients versus non-MS matched controls, with regard to age- and sex-standardized prevalence rates and odds ratios between the two populations. Differences in incidence rates in infections were analyzed between MS and nonMS counterparts.
Results
A total of 3,013 individuals with MS were matched with 15,103 control patients in a primary care database. A heightened prevalence of comorbid chronic diseases in patients with MS was found, in particular in ophthalmological (OR 1.57; 95% CI 1.38 – 1.79), neurological (OR 1.44; 95% CI 1.25 – 1.66), oncological (OR 1.21 (1.07 – 1.37); in particular kidney cancer, non-leukemia hematological malignancy and skin cancer) and psychiatric diseases (OR 1.17; 95% CI 1.03 – 1.33). Both older age and female sex were associated with higher risk of comorbidities in MS patients. In our cohort, the prevalence of autoimmune disorders was not statistically higher in MS patients compared to matched controls. The crude annual rate of infections in patients with MS was higher than in matched controls (respectively 0.6 versus 0.3 annual infectious episodes), with a heightened risk of infections of 86% in MS patients.
Conclusion
Patients living with MS have more chronic comorbidities and are at a considerable heightened risk of infections. The increased risk of certain oncological diseases in our cohort warrants further research, with a focus on demographic risk factors and the influence of disease-modifying treatments.
Prevention and treatment of these diseases may potentially ameliorate disease course and prognosis of MS.
Disclosure of interest
BdJ receives research funding from the Dutch MS Research Foundation, National MS Foundation, Dutch Multiple Sclerosis Association, Zorgverzekeraars Nederland (i.e. umbrella organization of health insurers in the Netherlands).
Gegevensverzameling
